Ornithine Transcarbamylase Deficiency Clinical Trial
Official title:
Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI
The purpose of this study is to use various types of MRI and cognitive testing to evaluate changes in the brain and cognitive function that occur in subjects with ornithine transcarbamylase deficiency (OTCD) relative to healthy individuals
The overall goal of this project is to characterize metabolic, structural and cognitive changes in OTCD using 1H MRS, DTI, volumetric averaging and fMRI with cognitive testing of executive function measures to validate biomarkers for the effect of HA and its treatment on the brain. The investigators will measure gln and mI in blood and brain (using 1H MRS) in affected participants, and mI in brain in controls, fractional anisotropy as a measure of white matter microstructural damage (by DTI) and brain activation pathways alterations with tasks probing working memory (fMRI). As a secondary outcome measure, the investigators will correlate the findings from neuroimaging with cognitive functioning. This protocol is based on the previous 5104 protocol, now includes children to evaluate the age and stage of disease on these indices in a cohort that is undergoing important developmental events against an age matched typically developing cohort. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Terminated |
NCT04717453 -
Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency
|
||
Recruiting |
NCT05910151 -
Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan
|
||
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT04612764 -
Liver Disease in Urea Cycle Disorders
|
||
Active, not recruiting |
NCT04442347 -
Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency
|
Phase 1 | |
Not yet recruiting |
NCT02670889 -
Urease Inhibitor Drug Treatment for Urea Cycle Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT05092685 -
Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn
|
Phase 1/Phase 2 | |
Completed |
NCT00472732 -
Neurologic Injuries in Adults With Urea Cycle Disorders
|
N/A | |
Terminated |
NCT04909346 -
Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
|
||
Completed |
NCT04416126 -
Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects
|
Phase 1 | |
Recruiting |
NCT05526066 -
Study for Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810
|
Phase 2 | |
Completed |
NCT00718627 -
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
|
Phase 2 | |
Recruiting |
NCT04908319 -
Hepatic Histopathology in Urea Cycle Disorders
|
||
Withdrawn |
NCT03767270 -
Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency
|
Phase 1/Phase 2 | |
Completed |
NCT04269122 -
A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects
|
||
Recruiting |
NCT06255782 -
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency (OTC-HOPE)
|
Phase 1/Phase 2 |